Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
One third of the population in the United States has nonalcoholic fatty liver disease
(NAFLD). Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to
cirrhosis.Currently, there is no proven therapy for patients with NASH. The investigators
core hypothesis is that therapy of patients with NASH with pentoxifylline (PTX) for one year
will result in improvement of biochemical parameters of liver disease and hepatic histology.
The focus of this proposal is on the effectiveness of pentoxifylline (PTX) in improving
laboratory and tissue parameters of liver disease, parameters of insulin-resistance, and
levels of cytokines in patients with NASH.